Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PODD

Insulet Corporation

Sep 20 • 03:05PM ET

235.43

Dollar change -2.25
Percentage change -0.95	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO SPY IVV VB VO RSP XLV IHI VUG

Index	S&P 500	P/E	42.75	EPS (ttm)	5.51	Insider Own	0.67%	Shs Outstand	69.91M	Perf Week	0.67%
Market Cap	16.51B	Forward P/E	61.05	EPS next Y	3.86	Insider Trans	-6.55%	Shs Float	69.64M	Perf Month	26.71%
Income	395.30M	PEG	2.87	EPS next Q	0.79	Inst Own	100.66%	Short Float	4.19%	Perf Quarter	15.35%
Sales	1.87B	P/S	8.82	EPS this Y	2.24%	Inst Trans	-0.62%	Short Ratio	3.91	Perf Half Y	41.28%
Book/sh	14.24	P/B	16.53	EPS next Y	28.30%	ROA	15.01%	Short Interest	2.92M	Perf Year	42.91%
Cash/sh	11.71	P/C	20.11	EPS next 5Y	14.90%	ROE	50.93%	52W Range	125.82 - 243.98	Perf YTD	8.50%
Dividend Est.	-	P/FCF	86.43	EPS past 5Y	122.47%	ROI	16.76%	52W High	-3.50%	Beta	1.21
Dividend TTM	-	Quick Ratio	2.68	Sales past 5Y	24.75%	Gross Margin	69.59%	52W Low	87.12%	ATR (14)	7.86
Dividend Ex-Date	-	Current Ratio	3.56	EPS Y/Y TTM	525.48%	Oper. Margin	14.56%	RSI (14)	72.28	Volatility	2.81% 3.66%
Employees	3000	Debt/Eq	1.40	Sales Y/Y TTM	27.82%	Profit Margin	21.11%	Recom	1.52	Target Price	239.05
Option/Short	Yes / Yes	LT Debt/Eq	1.36	EPS Q/Q	565.31%	Payout	0.00%	Rel Volume	0.57	Prev Close	237.68
Sales Surprise	0.10%	EPS Surprise	359.46%	Sales Q/Q	23.20%	Earnings	Aug 08 AMC	Avg Volume	746.92K	Price	235.43
SMA20	9.83%	SMA50	16.43%	SMA200	23.46%	Trades		Volume	370,277	Change	-0.95%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight	$235 → $340
Oct-18-22	Initiated	Barclays	Equal Weight	$238
Oct-12-22	Initiated	Jefferies	Hold	$260
Jul-11-22	Downgrade	Citigroup	Buy → Neutral	$310 → $250
Mar-02-22	Resumed	BofA Securities	Buy	$300
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy	$320
Feb-02-22	Upgrade	UBS	Neutral → Buy	$325
Jan-31-22	Upgrade	Oppenheimer	Perform → Outperform	$300 → $275
Jul-21-21	Resumed	Cowen	Outperform	$285 → $310
May-25-21	Initiated	Barclays	Overweight	$300
Apr-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$275 → $320

Show Previous Ratings

Sep-12-24 01:01PM	Insider Sale: Director Timothy Scannell Sells 5,000 Shares of Insulet Corp (PODD) (GuruFocus.com)
Sep-07-24 01:16AM	Insulets (PODD) Sales And Margins Surpassed Expectations (Insider Monkey)
Sep-05-24 07:22PM	Analyst Report: Insulet Corporation (Morningstar Research)
Sep-04-24 05:00PM	S&P 500 Gains and Losses Today: Dollar Tree Stock Tumbles After Earnings Miss (Investopedia)
Aug-30-24 10:35AM	Analyst Report: Insulet Corporation (Morningstar Research)
07:20AM	Loading…
07:20AM	Why Insulet Stock Was Zooming Higher This Week (Motley Fool)
01:46AM	Insider Sale at Insulet Corp (PODD): SVP & Chief Technology Officer Mark Field Sells Shares (GuruFocus.com)
Aug-28-24 05:25PM	S&P 500 Gains and Losses Today: Supermicro Stock Plunges on Annual Report Delay (Investopedia) +6.15%
Aug-27-24 05:36PM	S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index (Investopedia) +6.58%
12:48PM	Top Stock Movers Now: Nvidia, Insulet, Paramount Global, and More (Investopedia)
11:32AM	This Healthcare Stock Is the Best Performer in the S&P 500 After FDA Approval (Barrons.com)
10:08AM	Insulets Trang Ly on overcoming clinical inertia in diabetes care (MedTech Dive)
08:23AM	Insulet Omnipod cleared by FDA for type 2 diabetes (Medical Device Network)
Aug-26-24 04:20PM	Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes (Business Wire)
01:37PM	Insulet expands Omnipod 5 pump to people with Type 2 diabetes (MedTech Dive)
05:25PM	Loading…
Aug-20-24 05:25PM	S&P 500 Gains and Losses Today: Palo Alto Networks Surges After Earnings Beat (Investopedia) -6.87%
05:21PM	These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise (Investopedia)
12:11PM	Top Stock Movers Now: Boeing, Lowe's, Netflix, Eli Lilly, and More (Investopedia)
06:00AM	Insulet to Present at Upcoming Investor Conferences (Business Wire)
Aug-16-24 08:57PM	Insulet Corporation (PODD): This Diabetes Stock Is A Good Addition To Your Portfolio Now (Insider Monkey)
Aug-14-24 03:00AM	Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia (Business Wire)
Aug-10-24 01:04AM	Decoding Insulet Corp (PODD): A Strategic SWOT Insight (GuruFocus.com)
Aug-09-24 05:34PM	Analyst Report: Insulet Corporation (Morningstar Research) -8.81%
05:31PM	S&P 500 Gains and Losses Today: Expedia Soars as International Demand Drives Earnings Beat (Investopedia)
05:15PM	Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns (Investopedia)
01:19PM	Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Heres Why. (Barrons.com)
12:49PM	Top Stock Movers Now: Sweetgreen, Intel, Akamai Technologies, and More (Investopedia)
10:48AM	Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst (Benzinga)
09:24AM	Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised (Zacks)
Aug-08-24 08:07PM	Insulet inventory pressures cloud annual revenue forecast raise (Reuters)
05:30PM	Loading…
05:30PM	Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Insulet (PODD) Q2 Earnings Miss Estimates (Zacks)
04:07PM	Insulet: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year (Business Wire)
Aug-07-24 09:02AM	Earnings To Watch: Insulet Corp (PODD) Reports Q2 2024 Result (GuruFocus.com)
Aug-05-24 09:16AM	Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics (Zacks)
Aug-01-24 10:01AM	Insulet (PODD) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-26-24 09:37AM	Are Ozempic Jitters to Blame for DexCom's Stock-Price Plunge? (The Wall Street Journal)
06:00AM	Insulet Reports Preliminary Second Quarter 2024 Revenue Results (Business Wire)
Jul-18-24 12:00PM	All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy (Zacks)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire)
Jul-08-24 06:00AM	Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
Jun-25-24 02:32PM	Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 (Barrons.com)
Jun-24-24 04:08PM	Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks (Bloomberg)
08:36AM	Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes (Zacks)
08:13AM	Insulet seeks label expansion of Omnipod 5 for Type 2 diabetes (MedTech Dive)
07:13AM	Insulet plans label expansion for Omnipod in type 2 diabetes (Medical Device Network)
Jun-21-24 06:30PM	Insulets SECURE-T2D Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes (Business Wire)
10:59AM	Insulet (PODD) Faces Increasing Competition (Insider Monkey)
08:33AM	Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System (Zacks)
Jun-20-24 06:05AM	Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands (Business Wire)
06:00AM	Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates (Business Wire)
Jun-19-24 06:02AM	The 3 Best Diabetes Stocks to Buy in June 2024 (InvestorPlace)
Jun-17-24 07:01PM	Insider Sale at Insulet Corp (PODD) by SVP & Chief Technology Officer Mark Field (GuruFocus.com)
Jun-13-24 09:24AM	Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now? (Zacks)
Jun-11-24 07:00PM	Insider Sale: Director Timothy Scannell Sells 7,000 Shares of Insulet Corp (PODD) (GuruFocus.com)
Jun-06-24 06:19AM	7 Stocks That Could Safely 10X by 2030 (InvestorPlace)
May-30-24 09:59AM	PayPal upgraded, UiPath downgraded: Wall Street's top analyst calls (The Fly)
May-28-24 06:00AM	Insulet to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-24 09:50AM	Here's Why Insulet (PODD) is a Strong Momentum Stock (Zacks) -5.68%
May-22-24 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
May-19-24 02:08PM	Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains (InvestorPlace)
May-16-24 07:42AM	Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage (MedTech Dive)
May-14-24 04:47PM	S&P 500 Gains and Losses Today: Paramount Global Sinks as Sony Reconsiders Bid (Investopedia) +6.99%
04:44PM	Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market (Benzinga)
03:58PM	Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday? (Benzinga)
11:19AM	Insulet Shares Rise Despite Blue Orca's Short Position (MT Newswires)
May-13-24 10:48AM	Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised (Zacks)
May-10-24 04:55PM	S&P 500 Gains and Losses Today: Akamai Technologies Tumbles on Weak Guidance (Investopedia) -6.55%
03:25PM	Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:24PM	Insulet Corp (PODD) Reports Strong Q1 2024 Results and Raises Full-Year Guidance (GuruFocus.com)
09:43AM	Analyst Report: Insulet Corporation (Morningstar Research)
09:24AM	Raymond James Adjusts Price Target on Insulet to $213 From $218 (MT Newswires)
08:10AM	Wolfe Research Raises Price Target on Insulet to $205 From $200 (MT Newswires)
08:00AM	Canaccord Genuity Adjusts Price Target on Insulet to $234 From $226 (MT Newswires)
07:49AM	Jefferies Raises Price Target on Insulet to $260 From $255 (MT Newswires)
May-09-24 08:57PM	PODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:30PM	Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings (Zacks)
04:30PM	Insulet Q1 Earnings, Revenue Rise; 2024 Revenue Growth Boosted (MT Newswires)
04:11PM	Insulet: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year (Business Wire)
10:16AM	Nvidia, Micron and Super Micro among companies that shine in Wall Streets beat-and-raise game (MarketWatch)
May-07-24 06:00AM	Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth (Business Wire)
May-06-24 09:16AM	Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
May-02-24 06:15PM	Insulet (PODD) Rises Higher Than Market: Key Facts (Zacks)
09:50AM	Why Insulet (PODD) is a Top Momentum Stock for the Long-Term (Zacks)
Apr-28-24 05:50PM	American Politicians are Selling These 10 Stocks (Insider Monkey)
Apr-26-24 06:15PM	Insulet (PODD) Outperforms Broader Market: What You Need to Know (Zacks)
Apr-24-24 08:42AM	Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect (Zacks)
Apr-15-24 09:45AM	7 Stable Stocks for 50% Returns by Early 2025 (InvestorPlace)
Apr-12-24 12:10PM	Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-10-24 06:15PM	Insulet (PODD) Stock Moves -0.34%: What You Should Know (Zacks)
Apr-03-24 06:00AM	Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-02-24 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
Mar-28-24 09:55AM	Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High? (Zacks)
Mar-26-24 05:10AM	32 Countries with the Highest Rates of Diabetes (Insider Monkey)
Mar-21-24 09:17AM	Biogen, Moderna, and 6 More Healthcare Stocks That Wall Street Thinks Have Upside (Barrons.com)
06:40AM	Insulet names Ana Maria Chadwick CFO (MedTech Dive)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
06:00AM	Insulet Appoints Ana Maria Chadwick as Chief Financial Officer (Business Wire)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopfield Jessica	Director	Sep 11 '24	Option Exercise	29.87	7,628	227,848	34,545	Sep 12 04:07 PM
Hopfield Jessica	Director	Sep 11 '24	Sale	225.26	7,628	1,718,283	26,917	Sep 12 04:07 PM
Scannell Timothy J	Director	Sep 10 '24	Sale	225.84	5,000	1,129,200	30,586	Sep 11 04:13 PM
Hopfield Jessica	Director	Sep 11 '24	Proposed Sale	225.26	7,628	1,718,283		Sep 11 03:40 PM
Field Mark N	SVP & Chief Technology Officer	Sep 09 '24	Sale	220.87	1,383	305,463	9,761	Sep 10 04:16 PM
Budden Lauren	Group VP, CAO and Controller	Sep 09 '24	Sale	221.41	1,506	333,443	6,609	Sep 10 04:15 PM
Scannell Timothy J	Director	Sep 10 '24	Proposed Sale	225.84	5,000	1,129,210		Sep 10 02:27 PM
Field Mark N	Officer	Sep 09 '24	Proposed Sale	220.87	1,383	305,465		Sep 09 04:50 PM
Budden Lauren	Officer	Sep 09 '24	Proposed Sale	221.41	1,506	333,436		Sep 09 01:20 PM
Singh Prem	SVP, Global Operations	Aug 30 '24	Sale	202.27	1,824	368,940	3,656	Sep 03 04:30 PM
Singh Prem	Officer	Aug 30 '24	Proposed Sale	202.27	1,824	368,938		Aug 30 03:22 PM
Chadwick Ana Maria	EVP, CFO & Treasurer	Aug 29 '24	Buy	206.00	100	20,600	13,314	Aug 29 04:17 PM
Field Mark N	SVP & Chief Technology Officer	Aug 28 '24	Sale	203.00	1,387	281,561	11,347	Aug 29 04:14 PM
Field Mark N	Officer	Aug 28 '24	Proposed Sale	203.00	1,387	281,561		Aug 28 04:02 PM
Field Mark N	SVP & Chief Technology Officer	Jun 14 '24	Sale	199.96	1,500	299,940	12,875	Jun 17 04:11 PM
Scannell Timothy J	Director	Jun 10 '24	Sale	190.51	7,000	1,333,570	35,586	Jun 11 04:12 PM
Field Mark N	SVP & Chief Technology Officer	Jun 10 '24	Sale	190.43	2,131	405,806	14,375	Jun 11 04:11 PM
BORIO LUCIANA	Director	Jun 04 '24	Sale	182.58	360	65,729	3,298	Jun 05 04:13 PM
Scannell Timothy J	Director	May 28 '24	Option Exercise	32.33	18,267	590,595	45,886	May 29 04:04 PM
Scannell Timothy J	Director	May 28 '24	Sale	180.90	3,300	596,970	42,586	May 29 04:04 PM
Petrovic Shacey	Director	Feb 28 '24	Option Exercise	92.11	11,609	1,069,305	14,176	Feb 29 04:37 PM
Petrovic Shacey	Director	Feb 28 '24	Sale	162.92	11,609	1,891,338	2,567	Feb 29 04:37 PM
BORIO LUCIANA	Director	Dec 15 '23	Sale	207.08	72	14,910	2,278	Dec 18 04:01 PM
Petrovic Shacey	Director	Nov 13 '23	Option Exercise	81.69	20,000	1,633,733	22,567	Nov 14 04:04 PM
Petrovic Shacey	Director	Nov 13 '23	Sale	164.33	20,000	3,286,600	2,567	Nov 14 04:04 PM
Petrovic Shacey	Director	Nov 13 '23	Sale	165.02	15,000	2,475,300	0	Nov 14 04:04 PM

Open in Screener

EDIT

Editas Medicine Inc

Sep 20 • 03:05PM ET

3.78

Dollar change -0.13
Percentage change -3.45	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

EDIT Editas Medicine Inc daily Stock Chart

Held by: VTI XBI IWM VXF VB IWN IBB VBK DFAT SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	0.94%	Shs Outstand	81.77M	Perf Week	-4.43%
Market Cap	311.36M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	-1.35%	Shs Float	81.70M	Perf Month	-7.48%
Income	-193.45M	PEG	-	EPS next Q	-0.78	Inst Own	69.52%	Short Float	22.04%	Perf Quarter	-26.13%
Sales	67.03M	P/S	4.65	EPS this Y	-44.10%	Inst Trans	2.32%	Short Ratio	9.74	Perf Half Y	-51.79%
Book/sh	2.81	P/B	1.34	EPS next Y	5.67%	ROA	-41.75%	Short Interest	18.01M	Perf Year	-52.52%
Cash/sh	3.38	P/C	1.12	EPS next 5Y	1.70%	ROE	-61.23%	52W Range	3.40 - 11.69	Perf YTD	-62.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.88%	ROI	-76.61%	52W High	-67.71%	Beta	1.99
Dividend TTM	-	Quick Ratio	3.85	Sales past 5Y	101.57%	Gross Margin	91.33%	52W Low	11.03%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	3.85	EPS Y/Y TTM	20.53%	Oper. Margin	-317.78%	RSI (14)	44.45	Volatility	5.62% 5.54%
Employees	265	Debt/Eq	0.17	Sales Y/Y TTM	247.03%	Profit Margin	-288.59%	Recom	2.05	Target Price	13.80
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-45.51%	Payout	-	Rel Volume	0.76	Prev Close	3.91
Sales Surprise	-89.27%	EPS Surprise	-16.48%	Sales Q/Q	-82.23%	Earnings	Aug 07 BMO	Avg Volume	1.85M	Price	3.78
SMA20	0.88%	SMA50	-14.47%	SMA200	-42.67%	Trades		Volume	1,213,186	Change	-3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12
Nov-18-22	Downgrade	Credit Suisse	Outperform → Neutral	$25 → $13
Sep-29-22	Initiated	BofA Securities	Neutral	$18
Oct-19-21	Initiated	SVB Leerink	Mkt Perform	$41
Sep-24-21	Initiated	Stifel	Hold	$65
Sep-10-21	Upgrade	Oppenheimer	Perform → Outperform	$42 → $80
Aug-09-21	Upgrade	Truist	Hold → Buy	$45 → $80
Aug-05-21	Upgrade	Evercore ISI	Underperform → Outperform	$20 → $60
Jun-04-21	Resumed	Robert W. Baird	Outperform	$44
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$40

Show Previous Ratings

Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)
03:39AM	Q2 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:05AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -12.18%
07:07AM	Loading…
07:07AM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Second Quarter 2024 Results and Business Updates (GlobeNewswire)
Jul-31-24 07:00AM	Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update (GlobeNewswire)
Jul-17-24 11:30AM	3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-09-24 07:59AM	3 Profitable CRISPR Stocks Earning Analysts' Praise (InvestorPlace)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace) +5.01%
Jun-29-24 08:40PM	Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 09:04AM	What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential? (Insider Monkey)
Jun-26-24 09:33PM	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich (InvestorPlace)
04:36PM	Loading…
04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-25-24 08:00AM	3 Gene Editing Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-17-24 08:13AM	Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies (Zacks)
Jun-14-24 03:01AM	Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.83%
03:00AM	Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire)
Jun-07-24 11:30AM	Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
May-22-24 07:05PM	EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (GuruFocus.com) +9.26%
May-14-24 07:01PM	Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (GuruFocus.com) +5.63%
04:27PM	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing (MT Newswires)
10:00AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June (GlobeNewswire)
May-10-24 06:00AM	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.43%
01:12PM	1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? (Motley Fool)
12:40PM	Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down (Zacks)
11:33AM	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating (MT Newswires)
08:00AM	Loading…
08:00AM	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight (MT Newswires)
May-08-24 10:33PM	Q1 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
11:55AM	EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:25AM	Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-02-24 07:00AM	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
May-01-24 10:46AM	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration (MT Newswires)
08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
Apr-26-24 10:00AM	Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-22-24 04:31PM	Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? (Zacks)
Mar-07-24 03:31AM	1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. (Motley Fool)
Mar-05-24 11:52PM	Insider Sells Shares of Editas Medicine Inc (EDIT) (GuruFocus.com) -7.86%
Mar-04-24 10:30AM	1 Beaten-Down Stock With 55% Upside, According to Wall Street (Motley Fool) -5.79%
Mar-02-24 09:49PM	Why Editas Medicine Stock Soared as Much as 42% Higher This Week (Motley Fool)
Feb-29-24 11:26AM	Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.12%
08:42AM	Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up (Zacks)
Feb-28-24 11:15PM	Q4 2023 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) +24.94%
08:10AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials (GuruFocus.com)
07:08AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates (GlobeNewswire)
Feb-21-24 07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Feb-19-24 09:55AM	Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade (Zacks)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-06-24 12:00PM	What Makes Editas (EDIT) a New Buy Stock (Zacks)
Jan-31-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-24 08:45AM	2 Under-the-Radar Stocks With Incredible Upside Potential (Motley Fool)
Jan-21-24 09:37AM	Could Editas Medicine Become the Next CRISPR Therapeutics? (Motley Fool)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-15-24 05:19AM	Down 88%, Could Editas Medicine Be a Good Investment Now? (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 08:15AM	Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool)
Jan-03-24 07:00AM	Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.11%
Jan-02-24 10:15AM	Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why (Zacks)
Dec-23-23 08:02AM	Editas Just Caught a Break Thanks to Vertex Pharmaceuticals (Motley Fool)
Dec-14-23 08:32AM	Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6% (Zacks)
06:30AM	Editas cashes in on CRISPR patent with Vertex deal (BioPharma Dive)
Dec-13-23 05:12PM	S&P 500 Gains and Losses Today: Regional Banks Get a Boost From the Fed (Investopedia) +5.69%
04:06PM	Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal (Investopedia)
12:30PM	Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss (Investopedia)
09:00AM	Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 (GlobeNewswire)
Dec-11-23 01:22PM	ASH23: Pharma branding, Editas high bar and clinical trial diversity (BioPharma Dive) -5.71%
12:00PM	Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-05-23 07:00AM	1 Promising Stock Down 66% That Could Skyrocket in 2024 (Motley Fool)
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-22-23 06:30AM	Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year (InvestorPlace)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +10.84% -6.64%
05:36AM	2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street (Motley Fool)
Nov-16-23 03:25PM	3 Long-Term Growth Stocks Analysts Are Bullish On (InvestorPlace)
Nov-09-23 03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace) -6.31%
Nov-06-23 09:00AM	Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
Nov-05-23 05:51PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:45AM	Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +18.21%
08:34AM	Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ... (GuruFocus.com)
07:17AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2023 Results and Business Updates (GlobeNewswire)
Nov-02-23 09:12AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 07:00AM	Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly) +5.12%
01:53AM	The Trade Desk cleans up; DraftKings 'stronger than ever': 5 big analyst picks (Investing.com)
Oct-18-23 11:05AM	3 Gene Editing Stocks to Generate Super-Charged Gains (InvestorPlace)
09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool)
Oct-17-23 11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks) -6.20%

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Sep 04 '24	Sale	3.42	518	1,774	133,895	Sep 06 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 04 '24	Sale	3.42	1,555	5,325	313,724	Sep 06 04:18 PM
O'Neill Gilmore Neil	Officer	Sep 03 '24	Proposed Sale	3.92	3,000	11,760		Aug 29 04:19 PM
Mei Baisong	Officer	Sep 03 '24	Proposed Sale	3.92	1,000	3,920		Aug 29 04:17 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 25 '24	Sale	5.42	11,886	64,370	73,136	Jul 26 05:02 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jul 19 '24	Sale	5.21	6,619	34,456	134,413	Jul 22 05:01 PM
O'Neill Gilmore Neil	CEO	Jun 04 '24	Sale	5.50	12,191	66,997	315,279	Jun 06 04:17 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jun 04 '24	Sale	5.50	511	2,808	141,032	Jun 06 04:16 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	May 20 '24	Sale	5.61	22,337	125,404	116,829	May 22 04:30 PM
Hopfield Jessica	Director	May 13 '24	Buy	5.64	45,000	253,868	67,700	May 14 04:17 PM
O'Neill Gilmore Neil	CEO	Mar 05 '24	Sale	9.42	77,824	732,884	327,470	Mar 05 08:00 PM
Mei Baisong	SVP, CHIEF MEDICAL OFFICER	Mar 04 '24	Sale	9.42	20,327	191,425	141,543	Mar 05 07:54 PM
Eaton Bruce	EVP, CBO AND CTO	Dec 05 '23	Sale	10.90	103	1,122	74,791	Dec 07 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 14 '23	Sale	8.21	695	5,706	74,894	Nov 16 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 07 '23	Sale	8.40	139	1,168	75,589	Nov 09 04:31 PM

PODD

Insulet Corporation

EDIT

Editas Medicine Inc

Upgrade your FINVIZ experience